CART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital)

N/A

Report date: 2023/08/28 20:00:45

Base Information

Drug NameCART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital)
Drug Alias NameAnti-BCMA CAR-T cells Therapy(Institute Of Hematology & Blood Diseases Hospital)Autologous BCMA-directed CAR-T cells Therapy(Institute Of Hematology & Blood Diseases Hospital)
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMAT lymphocyte replacements
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInstitute Of Hematology & Blood Diseases Hospital
China Registration ClassN/A

Develop Information

Active CompaniesHebei Tahoe Chunyu Biotechnology Co LtdInstitute Of Hematology & Blood Diseases Hospital
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A